Xpert® vanA
The first rapid & accurate test to assist with VRE surveillance
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
Unit price
Product is not available for purchase in your region.
Collection devices
product image
Collection Device (Pack of 50)
Unit price
Product is not available for purchase in your region.
Error adding items to cart. If this error persists, please contact Digital Support

The Need

According to the Centers for Disease Control and Prevention (CDC), about 30% of all healthcare-associated enterococcal infections are caused by Vancomycin-Resistant Enterococci (VRE).1 However, VRE can be even more prevalent in high risk groups, such as immunocompromised and ICU patients.
The human and financial impact of VRE is high2:
  • Attributable mortality: 10%
  • Extended length of stay: 6.2 days
  • Incremental cost: $12,800
* With EAT (Early Assay Termination), for Positive Results
(1)CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.
(2)Carmeli Y, et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002 Oct 28;162(19):2223-8.

The Solution

The CDC and SHEA have both published guidelines on how to reduce or eliminate healthcare associated infections.3,4 As a part of a quality infection control program, Cepheid's Xpert vanA provides:
  • Rapid and accurate detection of the vanA gene most closely associated with VRE colonization
  • Superior NPV required in a surveillance test
  • Easy-to-use test with minimal hands-on time
(3)Siegel JD, et al. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007 Dec;35(10 Suppl 2):S165-93.
(4)Muto CA, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003 May;24(5):362-86.